Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Pegbelfermin in Healthy, Overweight, and Obese Participants
NCT04493567Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2020
- Primary completion
- Jun 2021
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pegbelfermin in Nonalcoholic steatohepatitis (NASH) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed serum concentration up to 29 days, Area under the serum concentration-time curve from time zero to time of last quantifiable concentration up to 29 days and 1 more. Started Jul 2020; status: completed.
02
Drugs
pegbelfermin
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04493567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04493567.